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AMPA and kainate receptors, along with NMDA receptors, are distinct subtypes of glutamate ion channels. 
Excessive activity of AMPA and kainate receptors has been implicated in neurological diseases, such as epilepsy 
and neuropathic pain. Antagonists that block their activities are therefore potential drug candidates. In a recent 
article in the Journal of Biological Chemistry by Jaremko et al. 2017, we have reported on the discovery and 
molecular characterization of an RNA aptamer of a dual functionality: the full-length RNA (101 nucleotide) 
inhibits AMPA receptors while the truncated or the short (55 nucleotide) RNA inhibits both the AMPA and 
kainate receptors. The full-length RNA aptamer was isolated through a specially designed, systematic evolution 
of ligands by exponential enrichment (SELEX) using only a single type of AMPA receptors expressed in 
HEK-293 cells. The design feature and the results of our recent article are highlighted here, as they demonstrate 
the utility of the SELEX approach and the potential of using a single AMPA receptor type to develop potent, 
novel RNA aptamers targeting multiple subunits and AMPA/kainate receptor subtypes with length-dependent 
functionalities. 
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Developing RNA therapeutics for treatment of a disease 
could begin from using SELEX [1-3] to screen and isolate 
candidate RNAs from a large RNA library against the target 
of interest. Such an exercise normally involves a single target 
(e.g., protein or receptor) with the intent of identifying 
aptamers with a single target specificity. Indeed, aptamers 
that can even discriminate against different conformations [4], 
different functional groups [5, 6], and even an amino acid 
mutation [7] on a target have been reported. To achieve target 
specificity through SELEX, one routinely uses a strong 
chemical pressure, such as an inhibitor that binds to the same 
site or mutually exclusive sites on that single target, in order 
to displace and enrich target-specific aptamers through in 
vitro evolution. However, there could be a utility of using the 
same target in SELEX to purposely evolve RNA aptamers 
with intended actions against multiple targets for drug 
discovery. This approach is based on the assumption that 
these targets are all involved in a disease. This approach may 
be especially useful with the application of SELEX to 
isolating aptamers against membrane proteins that must be 
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expressed in a heterologous expression system such as 
HEK-293 cells. Expressing a single target, i.e., one protein or 
receptor, to maximize the surface expression and density as 
opposed to expressing multiple receptors with “diluted” 
surface density for any one of the targets would be an 
advantage for this approach. In a recent article in the Journal 
of Biological Chemistry by Jaremko et al. 2017[8], we have 
reported such an approach for the discovery and molecular 
characterization of an RNA aptamer that has a 
length-dependent, dual functionality against AMPA and 
kainate receptors.  
AMPA and kainate receptors, along with the 
N-methyl-D-aspartate (NMDA) receptors, are distinct
subtypes of the glutamate ion channel receptor family. These
receptors mediate the majority of excitatory
neurotransmission in the mammalian central nervous system
(CNS) and are indispensable for brain development and
function [9-11]. AMPA and kainate receptors are more alike in
both sequence and structure, as compared with NMDA
receptors [11, 12]. AMPA receptors have 4 subunits, GluA1-4,
while kainate receptors have five subunits, GluK1-5.
Functionally, AMPA receptors are expressed
post-synaptically and are involved in fast excitatory
neurotransmission [9]. Kainate receptors are expressed both
pre- and post-synaptically; they contribute to excitatory
neurotransmission and also modulate network excitability by
regulating neurotransmitter release [13, 14].
AMPA and kainate receptors are involved in neurological 
diseases. A study of GluK2-deficient mice has revealed that 
hippocampal neurons in the CA3 region express both AMPA 
and kainate receptors, and both receptor types are involved in 
seizures [15]. Entorhinal cortex, a highly epilepsy-prone brain 
region, also expresses GluA1-4 and GluK5 [16]. In both 
human patients and animal models of temporal lobe epilepsy, 
the axons of granule cells that normally contact CA3 
pyramidal cells sprout to form aberrant glutamatergic 
excitatory synapses onto dentate granule cells [17-19]. The 
formation of aberrant mossy fiber synapses onto dentate 
granule cells has been suggested to induce the recruitment of 
kainate receptors in chronic epileptic rats. These granule cells 
express AMPA receptors as well, especially GluA1 and 
GluA2 subunits [20]. Another example of a neurological 
disorder that involve both AMPA and kainate receptor types 
is acute and chronic pain mediated through interior cingulate 
cortex [21, 22]. Interestingly, AMPA and KA receptors have 
been also implicated in osteoarthritis and rheumatoid arthritis 
[23]. Specifically, both receptors are expressed in human 
arthritis tissue. In rat models of antigen-induced arthritis, the 
use of the AMPA/KA receptor antagonist NBQX was shown 
to alleviate inflammation, pain and joint degeneration [23]. 
These lines of evidence therefore suggest that antagonists 
capable of blocking the activity of both AMPA and kainate 
receptors in vivo should be therapeutically useful. In fact, a 
nonselective AMPA/kainate receptor inhibitor, tezampanel 
(NGX424; Torrey Pines Pharmaceutics), reduced both 
migraine pain and other symptoms in a Phase II trial. 
NS1209 (NeuroSearch A/S), another nonselective 
AMPA/kainate receptor antagonist, was also shown in Phase 
II studies to alleviate refractory status epilepticus and 
neuropathic pain [24]. In this context, RNA aptamers with 
dual actions on both AMPA and kainate receptors would be a 
class of water-soluble antagonists, alternative to 
small-molecule inhibitors. 
The hypothesis we tested was based on the assumption 
that an RNA exerts a variety of tertiary interactions with its 
target(s) (i.e., hydrophobic and electrostatic interactions, 
hydrogen bonding and van der Walls forces) [25], and the 
types and the strengths of these interactions should be length 
(and sequence) dependent. If we can find an aptamer that 
covers a sufficient range of these interactions with two 
targets, it is possible that different subsets of these 
interactions may be differentially used for the two targets – 
truncation of the length, thereby fine-tuning these subsets of 
interactions, may decouple the differential molecular 
recognitions and specificities. To test this hypothesis, namely 
finding an aptamer that may act on both AMPA and kainate 
receptors but by using a single receptor as the target of 
selection in SELEX, we designed our approach based on the 
following rationale. (i) AMPA and kainate receptors share a 
high degree of sequence and structural homologies [10, 12]. (ii) 
Given its size (100 nucleotides in length as in our library), an 
RNA may bind to the surface of a receptor topologically. As 
a result, the larger area of interaction with the receptor, as 
compared with the interaction of a small molecule, may 
generate a range of size-dependent, multivalent binding 
interactions so that an RNA could bind to and inhibit AMPA 
and kainate receptors. In contrast, using multiple targets may 
likely lead to the identification of individual aptamers with 
singular activity. (iii) We further decided to choose an 
AMPA receptor, rather than a kainate receptor, as that single 
receptor target for SELEX, based on the fact that there are far 
more inhibitors of AMPA receptors [26] than those of kainate 
receptors [27]. Developing antagonists against kainate 
receptors in general has been far more challenging [27]. 
Among all possible AMPA receptor types, we chose 
GluA1/2R as the target of selection. GluA1/2R is an 
important channel type found in vivo [28-31]; here GluA2R is 
the edited isoform at the glutamine/arginine (Q/R) site of the 
GluA2 AMPA receptor subunit. (iv) Finally, instead of 
choosing an inhibitor or a binder to displace RNAs, we used 
urea after the binding step to denature both the target and 
possibly all bound RNA molecules, thereby allowing us to 
select and screen the maximal number of RNA molecules 
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bound to all possible sites on the target. It should be further 
noted that the choice of using GluA1/2R AMPA receptor 
channel type seemed more appropriate, because to date, there 
is no known selective antagonist targeting the GluA1/2R 
channel type. Therefore, all of these design features were 
intended to maximize the possibility of finding an RNA 
aptamer potentially with a broad range of activity. 
Using our design approach and SELEX, we successfully 
isolated an aptamer, which we termed as “AB9” aptamer (101 
nt), and a series of truncations of the full-length RNA led to a 
55-nt RNA, which we termed as “AB9s” (Figure 1) [8]. There 
are several interesting features about AB9 and its short version 
AB9s. First, the full-length aptamer inhibits AMPA receptors 
(red columns symbolize all AMPA receptor subunits in 
Figure 1). In fact, AB9 is more selective towards the 
GluA1/2R, the SELEX target. Not surprisingly, AB9 also 
inhibits GluA1 and 2 AMPA receptor subunits. However, 
AB9s, the short, 55-nt RNA, inhibits both the AMPA and 
kainate receptors (Figure 1, the lower bar graph, purple 
columns for the kainate receptors). Second, AB9 and AB9s 
appear to have different binding profiles and dissociation 
kinetics, measured with the use of 32P-labeled aptamers. AB9 
is slower to dissociate from the target, whereas AB9s is fast, 
suggesting a difference in interacting with their respective 
sites. Removing the central sequence segment (see secondary 
structures as predicted by MFold in Figure 1) has turned AB9 
into a much better inhibitor of the GluK1 and GluK2, the two 
key kainate receptor subunits, although the origin of this 
enhancement due to a smaller size, as compared with the full 
size aptamer, is unclear at the present. Nonetheless, these 
results are consistent with the assumption that both receptors 
Figure 1. AB9 and AB9s inhibit AMPA and kainate receptors in a length dependent manner. The Mfold predicted structures for AB9 and 
AB9s are shown on the left. The red and blue regions represent sequence stretches essential for function (inhibition). AB9 (full length, 101 
nucleotides in length) inhibits more selectively AMPA receptors, whereas AB9s (55 nucleotides in length inhibits both AMPA and KA receptors 
(see the bar graphs on the right). In the middle are two cartoon drawings of the AMPA receptors (red/green) and kainate receptors (blue/purple). 
For functional assay, each receptor was transiently expressed in HEK-293 cells. Whole-cell current recording was used to measure the 
whole-cell current amplitude in the absence, A, and presence of an aptamer, A(I) (in these bar graphs, 2 µM aptamer was used in each assay). 
The potency and the selectivity of an aptamer against the open-channel, and the closed-channel state are assayed [8]. 
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share high degree structural homology and perhaps even a 
high degree of homology in sites or “druggable” sites. As 
expected, neither aptamer has any effect on NMDA receptors 
(Figure 1, bar graphs). 
Our aptamers are better than the existing AMPA and 
kainate receptor antagonists by several measures. First, 
virtually all known kainate receptor antagonists generally 
have a stronger selectivity towards GluK1 than any other 
kainate receptor subunits [27]. Almost all that inhibit GluK2 
actually have stronger potency towards GluK1 [27]. In this 
context, it is unique that AB9s is nearly equally effective in 
inhibiting both the GluK1 and GluK2 kainate receptors. 
Second, AB9s further possesses a nearly identical potency 
for both the AMPA and kainite receptors (Figure 1). Yet, 
among the existing inhibitors of either AMPA or kainate 
receptors, NBQX does inhibit roughly equally well both 
GluK1 and GluK2; but NBQX is considered an AMPA 
receptor inhibitor, because it inhibits AMPA receptors 
>8-fold stronger than it does on kainate receptors [27].
Glutamylaminomethyl sulfonic acid marginally distinguishes
kainate from AMPA receptors, based on various in vivo and
in vitro tests, including a test in a seizure model [32-35]. Yet,
GAMS shows a significant antagonism on NMDA receptors
[36]. In contrast, AB9s can block the activity of both AMPA
and kainate receptors equally well without appreciable
NMDA receptor activity. In addition, because the aptamer is
an RNA molecule, it is a water soluble antagonist, different
from almost all of the existing antagonists for either AMPA
or kainate receptors.
The experimental design by which we used a single 
SELEX target (i.e., GluA1/2R) in a single SELEX operation 
to evolve a single RNA aptamer that acts on both the AMPA 
and kainate receptors, depending on its length, turns out to be 
an effective way of generating RNA inhibitors with a 
desirable inhibitory versatility. It should be noted that the 
success of this approach relies on high degree sequence and 
structural similarities not only between the kainate and 
AMPA receptor subtypes but also within a single receptor 
subtype. More precisely, no place shows a higher structural 
similarity than the site to which AB9 binds, although at the 
moment, we do not know where this site is. We do know, 
however, this site is a noncompetitive one [8]. It is highly 
likely that the “footprint” of AB9 site covers a larger surface 
area, which is needed to inhibit more selectively AMPA 
receptors. A short version (AB9s), however, uses perhaps 
only partial footprint, enough for recognizing and effectively 
inhibiting kainate receptors. In fact, as seen in the two bar 
graphs, the enhancement of the kainate receptor antagonism 
in the short RNA aptamer is actually at the expense of 
diminishing slightly the AMPA receptor potency. Finally, the 
existence of this site(s), full or partial, further suggests a 
possibility of developing chemically modified RNA aptamers 
amenable for in vivo application as therapeutic RNAs.  
Conflicting interests 
The authors have declared that no conflict of interests 
exist.  
Acknowledgements 
This work was supported by grants from the National 
Institutions of Health (R01 NS060812) and the Muscular 
Dystrophy Association. 
Author Contributions 
W.J., Z.H. and L.N. designed all the experiments. W.J.
and Z.H. performed all SELEX experiments; W.W., A.W. 
and N.K. performed electrophysiology experiments and data 
analysis; W.J. and L.N. wrote the manuscript draft. All 
authors edited the manuscript. 
Abbreviations 
AMPA: α-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid; CNS: central nervous system; 
HEK-293 cells: human embryonic kidney cells; NMDA, 
N-methyl-D-aspartate; nt: nucleotide; SELEX: systematic
evolution of ligands by exponential enrichment.
References 
1. Tuerk C, Gold L. Systematic evolution of ligands by exponential
enrichment: RNA ligands to bacteriophage T4 DNA polymerase.
Science 1990; 249:505-510.
2. Ellington AD, Szostak JW. In vitro selection of RNA molecules
that bind specific ligands. Nature 1990; 346:818-822.
3. Robertson DL, Joyce GF. Selection in vitro of an RNA enzyme
that specifically cleaves single-stranded DNA. Nature 1990;
344:467-468.
4. Geiger A, Burgstaller P, von der Eltz H, Roeder A, Famulok M.
RNA aptamers that bind L-arginine with sub-micromolar
dissociation constants and high enantioselectivity. Nucleic Acids
Res 1996; 24:1029-1036.
5. Jenison RD, Gill SC, Pardi A, Polisky B. High-resolution
molecular discrimination by RNA. Science 1994; 263:1425-1429.
6. Sassanfar M, Szostak JW. An RNA motif that binds ATP. Nature
1993; 364:550-553.
7. Chen L, Rashid F, Shah A, Awan HM, Wu M, Liu A, et al. The
isolation of an RNA aptamer targeting to p53 protein with single
amino acid mutation. Proc Natl Acad Sci U S A 2015;
112:10002-10007.
8. Jaremko WJ, Huang Z, Wen W, Wu A, Karl N,Niu L.
Identification and characterization of RNA aptamers: A long
aptamer blocks the AMPA receptor and a short aptamer blocks
both AMPA and kainate receptors. J Biol Chem 2017;
292:7338-7347.
9. Palmer CL, Cotton L, Henley JM. The molecular pharmacology
and cell biology of
RNA & DISEASE 2019; 6: e1560. doi: 10.14800/rd.1560; © 2019 by William J. Jaremko, et al. 
http://www.smartscitech.com/index.php/rd 
Page 5 of 5 
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptors. Pharmacol Rev. 2005; 57:253-277.  
10. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM,
Ogden KK, et al. Glutamate receptor ion channels: structure,
regulation, and function. Pharmacol Rev 2010; 62:405-496.
11. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate
receptor ion channels. Pharmacol Rev 1999; 51:7-61.
12. Zhu S, Gouaux E. Structure and symmetry inform gating
principles of ionotropic glutamate receptors. Neuropharmacology
2017; 112:11-15.
13. Contractor A, Mulle C, Swanson GT. Kainate receptors coming of
age: milestones of two decades of research. Trends Neurosci 2011;
34:154-163.
14. Bortolotto ZA, Lauri S, Isaac JT, Collingridge GL. Kainate
receptors and the induction of mossy fibre long-term potentiation.
Philos Trans R Soc Lond B Biol Sci 2003; 358:657-666.
15. Mulle C, Sailer A, Perez-Otano I, Dickinson-Anson H, Castillo
PE, Bureau I, et al. Altered synaptic physiology and reduced
susceptibility to kainate-induced seizures in GluR6-deficient mice.
Nature 1998; 392:601-605.
16. Borbely S, Czege D, Molnar E, Dobo E, Mihaly A,Vilagi I.
Repeated application of 4-aminopyridine provoke an increase in
entorhinal cortex excitability and rearrange AMPA and kainate
receptors. Neurotox Res 2015; 27:441-452.
17. Nadler JV. The recurrent mossy fiber pathway of the epileptic
brain. Neurochem Res 2003; 28:1649-1658.
18. Represa A, Tremblay E, Ben-Ari Y. Kainate binding sites in the
hippocampal mossy fibers: localization and plasticity.
Neuroscience 1987; 20:739-748.
19. Sutula TP, Dudek FE. Unmasking recurrent excitation generated
by mossy fiber sprouting in the epileptic dentate gyrus: an
emergent property of a complex system. Prog Brain Res 2007;
163:541-563.
20. Hagihara H, Ohira K, Toyama K, Miyakawa T. Expression of the
AMPA Receptor Subunits GluR1 and GluR2 is Associated with
Granule Cell Maturation in the Dentate Gyrus. Front Neurosci
2011; 5:100.
21. Bliss TV, Collingridge GL, Kaang BK, Zhuo M. Synaptic
plasticity in the anterior cingulate cortex in acute and chronic pain.
Nat Rev Neurosci 2016; 17:485-496.
22. Wu LJ, Zhao MG, Toyoda H, Ko SW,Zhuo M. Kainate
receptor-mediated synaptic transmission in the adult anterior
cingulate cortex. J Neurophysiol 2005; 94:1805-1813.
23. Bonnet CS, Williams AS, Gilbert SJ, Harvey AK, Evans BA,
Mason DJ. AMPA/kainate glutamate receptors contribute to 
inflammation, degeneration and pain related behaviour in 
inflammatory stages of arthritis. Ann Rheum Dis 2015; 
74:242-251.  
24. Swanson GT. Targeting AMPA and kainate receptors in
neurological disease: therapies on the horizon?
Neuropsychopharmacology 2009; 34:249-250.
25. Gelinas AD, Davies DR, Janjic N. Embracing proteins: structural
themes in aptamer-protein complexes. Curr Opin Struct Biol 2016;
36:122-132.
26. Solyom S, Tarnawa I. Non-competitive AMPA antagonists of
2,3-benzodiazepine type. Curr Pharm Des 2002; 8:913-939.
27. Jane DE, Lodge D, Collingridge GL. Kainate receptors:
pharmacology, function and therapeutic potential.
Neuropharmacology 2009; 56:90-113.
28. Wisden W, Seeburg PH. A complex mosaic of high-affinity
kainate receptors in rat brain. J Neurosci 1993; 13:3582-3598.
29. Wenthold RJ, Petralia RS, Blahos J, II, Niedzielski AS. Evidence
for multiple AMPA receptor complexes in hippocampal CA1/CA2
neurons. J Neurosci 1996; 16:1982-1989.
30. Shi S, Hayashi Y, Esteban JA, Malinow R. Subunit-specific rules
governing AMPA receptor trafficking to synapses in hippocampal
pyramidal neurons. Cell. 2001; 105:331-343.
31. Lu W, Shi Y, Jackson AC, Bjorgan K, During MJ, Sprengel R, et
al. Subunit composition of synaptic AMPA receptors revealed by
a single-cell genetic approach. Neuron 2009; 62:254-268.
32. Zhou N, Hammerland LG, Parks TN.
Gamma-D-glutamylaminomethyl sulfonic acid (GAMS)
distinguishes kainic acid- from AMPA-induced responses in
Xenopus oocytes expressing chick brain glutamate receptors.
Neuropharmacology 1993; 32:767-775.
33. Davies J, Watkins JC. Role of excitatory amino acid receptors in
mono- and polysynaptic excitation in the cat spinal cord. Exp
Brain Res 1983; 49:280-290.
34. Davies J, Watkins JC. Depressant actions of
gamma-D-glutamylaminomethyl sulfonate (GAMS) on amino
acid-induced and synaptic excitation in the cat spinal cord. Brain
Res 1985; 327:113-120.
35. Wilding TJ, Huettner JE. Antagonist pharmacology of kainate-
and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid-preferring receptors. Mol Pharmacol 1996; 49:540-546.
36. Raigorodsky G, Urca G. Spinal antinociceptive effects of
excitatory amino acid antagonists: quisqualate modulates the
action of N-methyl-D-aspartate. Eur J Pharmacol 1990; 182:37-47.
